Abstract
Background Novel influenza viruses pose a potential pandemic risk. Rapid detection of novel influenza virus infection in humans is critical to characterizing the virus and facilitating the implementation of public health response measures.
Methods We use a probabilistic framework to estimate the likelihood that novel influenza virus cases would be detected under different community and healthcare (urgent care, emergency department, hospital admission, and intensive care unit) testing strategies while at low frequencies in the United States. Model parameters were informed by data on seasonal influenza virus activity and existing testing practices.
Results In a baseline scenario reflecting the presence of 100 infections of a novel virus with similar severity to seasonal influenza, the probability of detecting at least one infection per month was highest in urgent care settings (72%) and when random testing was conducted in the community (77%). However, urgent care testing was over 15 times more efficient (estimated as the number of cases detected per 100,000 tests) due to the larger number of tests required for community testing. In scenarios that assumed increased clinical severity of novel virus infection, probabilities of detection increased across all healthcare settings, with testing in hospital and ICU settings being most efficient.
Conclusions Our results suggest that novel influenza virus circulation is likely to be detected through existing healthcare surveillance, with the most efficient testing setting impacted by the disease severity profile. These analyses can help inform future testing strategies to maximize the likelihood of novel influenza detection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors have no funding sources to declare.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data were used solely to inform model inputs and were the result of secondary analyses; the original sources are cited in the text.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.
Data availability: All materials needed to perform the analysis will be made available at https://github.com/CDCgov upon publication. Data were used solely to inform model inputs and were the result of secondary analyses; the original sources are cited in the text.
The authors have no conflicts of interest or funding sources to declare.
Data Availability
All materials needed to perform the analysis will be made available at https://github.com/CDCgov upon publication. Data were used solely to inform model inputs and were the result of secondary analyses; the original sources are cited in the text.
